Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of ADXS opened at $0.02 on Monday. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The stock has a market capitalization of $852,660.00, a price-to-earnings ratio of 0.00 and a beta of 1.51. The stock has a fifty day moving average of $0.04 and a 200-day moving average of $0.29.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.